Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark broader industry growth?

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...

Tempus AI started off the year with a stellar ... a 79% YoY growth, bolstered by the Ambry Genetics acquisition and a rapidly growing TAM. Despite the deep selloff recently, I rank TEM a 'Strong ...

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech ...

In February 2025, Tempus AI, Inc. (NASDAQ:TEM) completed the acquisition of Ambry Genetics, enhancing its capabilities in genetic testing and data services. Tempus’s stock has experienced ...

Acquisitions Reinforce Clinical and Data Infrastructure: Tempus AI’s 2025 acquisitions of Deep 6 AI and Ambry Genetics have expanded its clinical footprint to more than 750 sites and 30 million ...